Tags

Type your tag names separated by a space and hit enter

Pharmacovigilance and post-black market surveillance.
Soc Stud Sci. 2009 Jun; 39(3):395-420.SS

Abstract

Pharmacovigilance can be defined as a set of practices aiming at the detection, understanding and assessment of risks related to the use of drugs in a population, and the prevention of consequential adverse effects. In a narrower sense, the term refers exclusively to postmarket surveillance. This paper briefly outlines how pharmacovigilance has come to play a central role in the regulation of novel pharmaceuticals. However, the focus of the text is on mechanisms emerging in an experimental drug scene that aim at dealing with the risks posed by 'designer drugs' newly introduced to the black market. This discussion of pharmacovigilance and 'post-black market surveillance' is situated in the broader context of the more recent dissemination of vigilance as a key element of government in a world too complex for legal and disciplinary measures alone.

Authors+Show Affiliations

Max Planck Institute for the History of Science, Berlin, Germany. nlanglitz@mpiwg-berlin.mpg.de

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19848184

Citation

Langlitz, Nicolas. "Pharmacovigilance and Post-black Market Surveillance." Social Studies of Science, vol. 39, no. 3, 2009, pp. 395-420.
Langlitz N. Pharmacovigilance and post-black market surveillance. Soc Stud Sci. 2009;39(3):395-420.
Langlitz, N. (2009). Pharmacovigilance and post-black market surveillance. Social Studies of Science, 39(3), 395-420.
Langlitz N. Pharmacovigilance and Post-black Market Surveillance. Soc Stud Sci. 2009;39(3):395-420. PubMed PMID: 19848184.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacovigilance and post-black market surveillance. A1 - Langlitz,Nicolas, PY - 2009/10/24/entrez PY - 2009/10/24/pubmed PY - 2009/11/18/medline SP - 395 EP - 420 JF - Social studies of science JO - Soc Stud Sci VL - 39 IS - 3 N2 - Pharmacovigilance can be defined as a set of practices aiming at the detection, understanding and assessment of risks related to the use of drugs in a population, and the prevention of consequential adverse effects. In a narrower sense, the term refers exclusively to postmarket surveillance. This paper briefly outlines how pharmacovigilance has come to play a central role in the regulation of novel pharmaceuticals. However, the focus of the text is on mechanisms emerging in an experimental drug scene that aim at dealing with the risks posed by 'designer drugs' newly introduced to the black market. This discussion of pharmacovigilance and 'post-black market surveillance' is situated in the broader context of the more recent dissemination of vigilance as a key element of government in a world too complex for legal and disciplinary measures alone. SN - 0306-3127 UR - https://www.unboundmedicine.com/medline/citation/19848184/Pharmacovigilance_and_post_black_market_surveillance_ L2 - http://journals.sagepub.com/doi/full/10.1177/0306312708101977?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -